It’s only fair to share… ATUZAGINSTAT, COR388 cas 2211981-76-7 Cyclopentanecarboxamide, N-[(1S)-5-amino-1-[2-(2,3,6-trifluorophenoxy)acetyl]pentyl]- Cyclopentanecarboxamide, n-((1s)-5-amino-1-(2-(2,3,6-trifluorophenoxy)acetyl)pentyl)-N-((3s)-7-amino-2-oxo-1-(2,3,6- trifluorophenoxy)heptan-3-yl)cyclopentanecarboxamide C19H25F3N2O3 386.415 UNII-DGN7ROZ8EN You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. Known as gingipains, these proteases penetrate gingival tissue and …
Category «Uncategorized»
Votoplam
It’s only fair to share… Votoplam CAS 2407849-89-0 Molecular Formula C21H25N9O Molecular Weight 419.4829 PHENOL, 2-(3-(2,2,6,6-TETRAMETHYL-4-PIPERIDINYL)-3H-1,2,3-TRIAZOLO(4,5-C)PYRIDAZIN-6-YL)-5-(2H-1,2,3-TRIAZOL-2-YL)-2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]-5-(triazol-2-yl)phenol UNII D7EZ7B585X Votoplam is a gene splicing modulator, used to inhibit Huntington’s disease. Target: DNA/RNA SynthesisPathway: Cell Cycle/DNA Damage Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive …
Atilotrelvir
It’s only fair to share… Atilotrelvir, BDBM622370, GST-HG171 2850365-55-6, ALIGOS THERAPEUTICS, INC 511.5 C24H32F3N5O4 (1S,3S,4R)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-2-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]spiro[2-azabicyclo[2.2.1]heptane-5,1′-cyclopropane]-3-carboxamide Spiro[2-azabicyclo[2.2.1]heptane-5,1′-cyclopropane]-3-carboxamide, N-[(1S)-1-cyano-2-[(3S)-2-oxo-3-pyrrolidinyl]ethyl]-2-[(2S)-3,3-dimethyl-1-oxo-2-[(2,2,2-trifluoroacetyl)amino]butyl]-, (1S,3S,4R)- Atilotrelvir (GST-HG171) is antiviral agent, can inhibit coronavirus, picornavirus and norovirus infection. SCHEME SYNTHESIS Patents are available for this chemical structure: https://patentscope.wipo.int/search/en/result.jsf?inchikey=GTRJFXDJASEGSW-KBCNZALWSA-N PATENT US20230312571, Embodiment 11 PATENT WO2023043816 EX 50 [0312] To a stirred mixture of (1R,4S,6S)-5-(tert-butoxycarbonyl)-5-azaspiro[bicyclo[2.2.1]heptane-2,1′-cyclopropane]-6-carboxylic acid (120 mg, 0.449 …
Zamaporvint
It’s only fair to share… Zamaporvint RXC004, PHASE 2 1H-IMIDAZOLE-1-ACETAMIDE, 5-METHYL-N-(5-(2-PYRAZINYL)-2-PYRIDINYL)-4-(2-(TRIFLUOROMETHYL)-4-PYRIDINYL)- 5-METHYL-N-(5-(2-PYRAZINYL)-2-PYRIDINYL)-4-(2-(TRIFLUOROMETHYL)-4-PYRIDINYL)-1H-IMIDAZOLE-1-ACETAMIDE UNII M56M7CHN8E Molecular Weight 439.39 Formula C21H16F3N7O CAS No. 1900754-56-4 Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. Zamaporvint targete membrane-bound o-acyltransferase Porcupine and inhibited Wnt ligand palmitoylation, secretion, and pathway activation. Zamaporvint displays a favorable pharmacokinetic profile and shows potent antiproliferative effects in Wnt ligand-dependent colorectal and …
ATICAPRANT
It’s only fair to share… ATICAPRANT JNJ-67953964, WHO 10582 1174130-61-0 BENZAMIDE, 4-(4-(((2S)-2-(3,5-DIMETHYLPHENYL)-1-PYRROLIDINYL)METHYL)PHENOXY)-3-FLUORO- C26H27FN2O2, 418.512 Aticaprant, also known by its developmental codes JNJ-67953964, CERC-501, and LY-2456302, is a κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder.[2][3][4] A regulatory application for approval of the medication is expected to be submitted by 2025.[2] Aticaprant is taken by mouth.[1] Side effects of aticaprant include itching, …
ZASTAPRAZAN
It’s only fair to share… ZASTAPRAZAN 2133852-18-1 362.5 g/mol, C22H26N4O JAQBO; JP-1366; OCN-101; Zastaprazan citrate – Onconic Therapeutics, UNII-W9S9KZX5MD Highest Development Phases Zastaprazan (JP-1366) is a proton pump inhibitor (WO2018008929). Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases. SCHEME Patent WO2018008929 PATENT KR1777971 //////////ZASTAPRAZAN, JAQBO, JP-1366, OCN-101, Zastaprazan citrate, Onconic Therapeutics, …
Deuruxolitinib
It’s only fair to share… Deuruxolitinib C17H18N6, 314.422 Fda approved Leqselvi, 7/25/2024, To treat severe alopecia areata C-21543, CTP 543, CTP-543, CTP543 (3r)-3-(2,2,3,3,4,4,5,5-d8)cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile 1h-pyrazole-1-propanenitrile, .beta.-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (.beta.r)-D8-ruxolitinib Ingredient UNII CAS InChI Key Deuruxolitinib phosphate 8VJ43S4LCM 2147706-60-1 JFMWPOCYMYGEDM-NTVOUFPTSA-N unii 0CA0VSF91Y Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata.[1] It is a Janus …
Zelatriazin
It’s only fair to share… Zelatriazin, C18H15F3N4O3, 392.3 g/mol 1929519-13-0 NBI-1065846 or TAK-041 Phase 2 (S)-2-(4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl)acetamide Zelatriazin (NBI-1065846 or TAK-041) is a small-molecule agonist of GPR139. It was developed for schizophrenia and anhedonia in depression but trials were unsuccessful and its development was discontinued in 2023.[1][2][3][4][5][6][7] SCHEME SYN WO2016081736 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016081736&_cid=P21-M0X9BK-38013-1 Example 2: (S)-2-(4-oxobenzo[d][l,2,3]triazin-3(4H)-yl)-N-(l-(4-(trifluoromethoxy)phenyl)ethyl)acetamide [0166] To a vial containing 2-(4-oxobenzo[d][l,2,3]triazin-3(4H)-yl)acetic acid (15 mg, …
Vorasidenib
It’s only fair to share… Vorasidenib6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine CAS 1644545-52-7, C14H13ClF6N6, 414.74 FDA APPROVED, 8/6/2024, Voranigo, To treat Grade 2 astrocytoma or oligodendroglioma UNII 789Q85GA8P Ingredient UNII CAS InChI Key Vorasidenib citrate X478M962XG 2316810-02-1 YOUTVRFNJAAFNS-DLVAHKFUSA-N Vorasidenib citrate anhydrous W4XG3EQK7B 2316810-00-9 OCEHQNOYRLHJCI-WPRTUUMNSA-N Vorasidenib, sold under the brand name Voranigo, is an anti-cancer medication used for the treatment of certain forms of glioma.[1][2] Vorasidenib …
Arbemnifosbuvir, AT-752, PD160572
It’s only fair to share… Arbemnifosbuvir, AT-752, 1998705-63-7, PD160572 E9V7VHK36U INN 12706 C24H33FN7O7P 581.5 g/mol SYN propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate L-ALANINE, N-((P(R),2’R)-2-AMINO-2′-DEOXY-2′-FLUORO-N,2′-DIMETHYL-P-PHENYL-5′ -ADENYLYL)-, 1-METHYLETHYL ESTERN-((P(R),2’R)-2-AMINO-2′-DEOXY-2′-FLUORO-N,2′-DIMETHYL-P-PHENYL-5′ -ADENYLYL)-L-ALANINE 1-METHYLETHYL ESTER WO2022040473 Atea Pharmaceuticals, Inc. CN113784721 US20160257706 WO2022076903 US10874687 PATENT US20160257706 https://patentscope.wipo.int/search/en/detail.jsf?docId=US177601863&_cid=P11-M0VTE4-38538-1 Example 1. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate Step 1. Preparation of ((2R,3R,4R,5R)-3-(benzoyloxy)-5-bromo-4-fluoro-4-methyltetrahydrofuran-2-yl)methyl benzoate (2) To a solution of (2R)-3,5-di-O-benzoyl-2-fluoro-2-C-methyl-D-ribono-γ-lactone (24.8 …